Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Walker Cancer Research Institute Inc. manages 2 pending office actions in the Chemistry & Materials technology area. These actions are split between 2 distinct examiners and 2 distinct art units. MCCLAIN, STARFARI TESHAWN is the busiest examiner with 1 pending office action. This distribution means that each of the company's pending matters is being handled by a different examiner in a different specialized division.
Even with a small portfolio of 2 pending office actions, the applicant must navigate two distinct examination environments. Practitioners should focus on the specific requirements of the 2 distinct art units involved. MCCLAIN, STARFARI TESHAWN is 1 of the examiners currently reviewing the company's chemistry-related applications. This ratio of actions to examiners and art units suggests a diverse technical scope within the chemistry and materials sector. Managing these distinct examiners requires a tailored approach for each individual case. This structure ensures that the company's innovations are evaluated from multiple specialized viewpoints.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCCLAIN, STARFARI TESHAWN | 1 | 91.2% | -12.5% |
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18904920 | SYNTHESES AND USES OF TRI-SUBSTITUTED MONO-HYDROGEN FERROCYANIDES FOR EFFICIENT HYDROXYL RADICAL GENERATORS | MCCLAIN, STARFARI TESHAWN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18390314 | CHEMICALS AND USE OF HYPOHALITES IN MECHANISM-BASED SELECTIVE DUAL RADICAL ORGANIC SYNTHESIS | CHANDRAKUMAR, NIZAL S | — |
| Art Unit | Apps |
|---|---|
| 1738 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18904920 | SYNTHESES AND USES OF TRI-SUBSTITUTED MONO-HYDROGEN FERROCYANIDES FOR EFFICIENT HYDROXYL RADICAL GENERATORS | MCCLAIN, STARFARI TESHAWN | 1738 | §102§103 | Non-Final OA | — | Pending | Oct 02, 2024 |
| 18390314 | CHEMICALS AND USE OF HYPOHALITES IN MECHANISM-BASED SELECTIVE DUAL RADICAL ORGANIC SYNTHESIS | CHANDRAKUMAR, NIZAL S | 1625 | §112 | Non-Final OA | — | Pending | Dec 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialWalker Cancer Research Institute Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Starfari Teshawn Mcclain has the most, with 1 of Walker Cancer Research Institute Inc.'s pending office actions.
Mostly Chemistry & Materials (USPTO Tech Center 1700), based on where its pending office actions are examined.
